



2015-04-24

PRESS RELEASE

Results from Oasmia's Phase III study will be presented at ASCO

Uppsala, Sweden – April 24, 2015. The pharmaceutical company Oasmia Pharmaceutical announced today that data from the recently completed Phase III study with Paclical® for treatment of ovarian cancer will be presented at the 2015 ASCO Annual Meeting in Chicago. The principal investigator of the study, Ignace Vergote, will perform the presentation.

ASCO (American Society for Clinical Oncology) is an organization for clinical oncologists and provides recommendations for clinical practices and publishes the scientific journal Journal of Clinical Oncology among other things.

The 2015 ASCO Annual Meeting will be held in Chicago between May 29 and June 2 and about 30 000 people with interests in clinical oncology will attend. It is the first time that Phase III data from the study is presented to the scientific community

"The results of this study are very important, because in this randomized phase III study including 789 patients with platinum-sensitive recurrent ovarian cancer, it was shown that Paclical is as effective as paclitaxel without the need for premedication to avoid allergic reactions. This is because Paclical is a Cremophor-free formulation of paclitaxel and we know that Cremophor is the reason for many allergic reactions on paclitaxel. In addition Paclical can be administered with a shorter infusion time than paclitaxel, which should result in cost savings for the hospitals" says Professor Ignace Vergote, Chairman Leuven Cancer Institute, University Hospital Leuven, Belgium"

"The ASCO Annual Meeting is one of the most important meetings for clinical oncologists and we are very pleased that professor Vergote finds our results interesting and wants to present them. It is a wonderful opportunity to raise awareness of Oasmia in the medical community" says Margareta Eriksson, Head of Clinical Development at Oasmia.

For more information, please contact:

Anders Lundin, Chief Financial Officer
Mobile: +46 70 20 96 300
E-mail: anders.lundin@oasmia.com

Notes to editors:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 10.10, CET on April 24, 2015."